Financial Report MR PHILIP POWELL BComm (Hons) ACA MAICD Non-Executive Director (appointed 17 June 2019) Mr Powell is a Chartered Accountant with extensive experience in investment banking, specialising in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in senior financial roles at OAMPS Ltd, a former ASX-listed financial services group, and 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. Mr Powell was a former Non-Executive Director of RMA Global Ltd (ASX: RMY), PolyNovo Ltd (ASX: PNV) and Medical Developments International Ltd (ASX: MVP). Mr Powell is the Chair of the Company’s Audit & Risk Committee. Mr Powell has not been a director of any listed companies in the last three years other than those listed above. INTERESTS IN THE SHARES AND OPTIONS OF THE COMPANY AND RELATED BODIES CORPORATE As at the date of issuing this report, the interests of the current directors in the shares of the Company were: Ordinary Shares Options Mr David Williams 4,999,337 6,450,000 Dr Geoffrey Cumming 177,414 250,000 Mr Max Johnston 404,310 250,000 Mr Philip Powell 474,630 250,000 EXECUTIVE MANAGEMENT AND COMPANY SECRETARY CHIEF EXECUTIVE OFFICER DR LEEARNE HINCH BSc BVMS MBA (appointed 7 November 2016) Dr Hinch is a seasoned biotechnology CEO and entrepreneur with a proven track record in corporate strategy, business management, capital raising, investor relations, M&A, business development and partnering. Leearne has successfully led INOVIQ’s transformation from a single-asset diagnostics company to a diversified biotech, through M&A, advancing its cancer diagnostics and therapeutics pipeline, securing a global commercial partner for its proprietary exosome capture tools and building an experienced team. She previously established lifesciences consulting firm Ingeneus Solutions Pty Ltd and has held past leadership roles as a biotechnology executive and consultant at Eustralis Pharmaceuticals Ltd, HealthLinx Ltd (ASX: HTX), OBJ Ltd (ASX: OBJ), Holista Colltech Ltd (ASX: HCT) and Chemeq Ltd (ASX: CMQ), where she gained extensive experience leading strategic, development and commercial programs across diagnostics, medical devices and therapeutics. Dr Hinch holds Bachelor of Science, Bachelor of Veterinary Medicine and Surgery and Master of Business Administration qualifications. CHIEF SCIENTIFIC OFFICER DR GREGORY RICE PhD BSc (Hon) MHA Grad Dip Mgt (appointed 20 September 2021) Dr Rice is an internationally recognised academic and commercial scientist with over 30 years’ expertise and experience in oncology, perinatology, exosome-based research, clinical translational research, IVD development and commercialisation. He has held senior academic appointments, co-founded hospital-based clinical research centres in both oncology and perinatology, and co-founded and led diagnostic companies. He is an award-winning scientist with a strong international profile and clinical research networks. He has published more than 280 peer-reviewed scientific publications and is a regular invited speaker at international conferences. He has held numerous academic leadership positions including at the University of Queensland (UQ), Baker Heart and Diabetes Institute, University of Melbourne, and Monash University. As Director of the UQ Centre for Clinical Diagnostics, he established the Centre, implemented an ISO17025 quality management system, secured NATA accreditation, and established an exosome research facility to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Additionally, he was a Founding Director and CSO of diagnostics company HealthLinx Ltd (ASX: HTX) and more recently CEO of Pregnostica SpA. His academic qualifications include a Doctor of Philosophy and Bachelor of Science (First Class Honours) from the University of Western Australia and a Graduate Diploma in Management and Master of Health Administration from RMIT University. 19 Annual Report 2024
RkJQdWJsaXNoZXIy MjE2NDg3